<DOC>
	<DOCNO>NCT01640678</DOCNO>
	<brief_summary>Autologous epidermal cell suspension graft effective method surgical treatment vitiligo , suitable treat large area well cosmetic result compare grafting method . The ReCell Autologous Cell Harvesting Device ( Avita Medical Europe Limited , Cambridge , UK ) autologous cell harvest device , compare form autologous epidermal cell suspension grafting , easy use show similar result . Furthermore , ReCell device need laboratory facility . Therefore , promise patient large vitiligo piebaldism lesion . Objectives : Primary : ass efficacy safety autologous epidermal cell suspension graft ReCell device CO2 laser abrasion compare CO2 laser abrasion alone treatment , patient piebaldism stable vitiligo . Secondary : assess practical aspect patient satisfaction autologous epidermal cell suspension graft ReCell device . Study design : Prospective observer blind randomize control pilot study . Study population : 10 patient â‰¥ 18 year stable segmental vitiligo piebaldism treatment Netherlands Institute Pigment Disorders ( NIPD ) Academic Medical Centre University Amsterdam . Methods : Three depigmented region trunk proximal extremity randomly allocate ; CO2 laser abrasion + ReCell autologous cell suspension grafting , CO2 laser abrasion , treatment . After transplantation , UV-treatment accord standard treatment protocol NIPD start site continue 3 month . Three six month graft , percentage repigmentation lesion assess .</brief_summary>
	<brief_title>Autologous Cell Suspension Grafting Using ReCell Vitiligo Piebaldism Patients</brief_title>
	<detailed_description />
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Piebaldism</mesh_term>
	<criteria>patient piebaldism Patients segmental vitiligo , stable since 12 month without systemic therapy topical therapy define absence new lesion and/or enlargement exist lesion least three depigmented skin lesion proximal extremity trunk large 3x3 cm one lesion least 9x3 cm Age &gt; 18 willing able give write informed consent UV therapy systemic immunosuppressive treatment last 12 month Local treatment vitiligo last 12 month Vitiligo lesion follicular nonfollicular repigmentation Skin type I Recurrent HSV skin infection Hypertrophic scar Keloid Cardial insufficiency Patients history hypersensitivity ( UVB UVA ) light and/or allergy local anesthesia . Patients pregnant breastfeed Patients competent understand procedure involve Patients atypical nevi Patients personal history melanoma nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>